BACKGROUND: The clinical performance of the Roche cobas e411 automated assay for the measurement of thyrotropin (TSH)-receptor antibodies (TRAbs) for the diagnosis of Graves' disease was evaluated in the setting of new referrals to a specialized thyroid clinic. METHODS: The final diagnosis of 102 new patients attending their first outpatient appointment at a thyroid clinic was correlated with the TRAbs result. In all cases, the diagnosis was made independently of the TRAbs result by the same consultant (ADT) based on clinical examination, thyroid function tests (TSH, free thyroxine, total triiodothyronine measured on Architect; Abbot Diagnostics), and a technetium-99m uptake and scan. TRAbs were measured using the cobas e411 (Roche Diagnostics). The clinical sensitivity and specificity of the assay were determined and compared with other published performance characteristics of the assay. RESULTS: Optimal sensitivity (95%) and specificity (98%) were obtained using a cut-off of 1.6 IU/L. The positive and negative predictive values at this cut-off were calculated as 98% and 94%, respectively. CONCLUSIONS: Using a cut-off of 1.6 IU/L, considered independently of thyroid function tests, the Roche cobas e411 automated immunoassay for TRAbs is a convenient, sensitive and specific tool for the differential diagnosis of hyperthyroidism.
BACKGROUND: The clinical performance of the Roche cobas e411 automated assay for the measurement of thyrotropin (TSH)-receptor antibodies (TRAbs) for the diagnosis of Graves' disease was evaluated in the setting of new referrals to a specialized thyroid clinic. METHODS: The final diagnosis of 102 new patients attending their first outpatient appointment at a thyroid clinic was correlated with the TRAbs result. In all cases, the diagnosis was made independently of the TRAbs result by the same consultant (ADT) based on clinical examination, thyroid function tests (TSH, free thyroxine, total triiodothyronine measured on Architect; Abbot Diagnostics), and a technetium-99m uptake and scan. TRAbs were measured using the cobas e411 (Roche Diagnostics). The clinical sensitivity and specificity of the assay were determined and compared with other published performance characteristics of the assay. RESULTS: Optimal sensitivity (95%) and specificity (98%) were obtained using a cut-off of 1.6 IU/L. The positive and negative predictive values at this cut-off were calculated as 98% and 94%, respectively. CONCLUSIONS: Using a cut-off of 1.6 IU/L, considered independently of thyroid function tests, the Roche cobas e411 automated immunoassay for TRAbs is a convenient, sensitive and specific tool for the differential diagnosis of hyperthyroidism.